Viatris (VTRS) Q1 2025 10-Q Quarterly Report
Viatris (VTRS) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 8, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Viatris Q1 2025 10-Q Analysis
Risk Factors
- • New risk: Potential U.S. tariffs on pharmaceutical imports triggered by recent tariff escalations and retaliations from other countries
- • Most material update: Increased cost and supply chain disruption risk from proposed tariffs affecting generics, possibly reducing net sales and profit margins
- • Regulatory risk: Need for regulatory approval before changing manufacturing locations or suppliers limits flexibility amid trade restrictions
- • Operational risk: Supply chain disruptions and manufacturing delays due to tariffs or domestic sourcing requirements threaten near-term production continuity
- • Financial risk: Tariff-related cost increases may reduce cash flows and impair ability to pay dividends or repurchase shares
Viatris Q1 2025 Quarterly FinancialsXBRL
Revenue
$3.2B
▼ -11.2% YoY
Net Income
-$3.0B
▼ -2770.8% YoY
Net Margin
-93.8%
▼ -9691bp YoY
Source: XBRL data from Viatris Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Viatris Quarterly Reports
Get deeper insights on Viatris
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.